# Regeneron Pharmaceuticals clinical trials: 412 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 412 trials with Regeneron Pharmaceuticals as lead sponsor, 83 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Regeneron Pharmaceuticals: 412 rows for $20.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 412
- Recruiting or not yet: 83
- Read on: November 19, 2026

## Trials

The 25 newest of 412, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| October 28, 2026 | NCT07901725 | Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed... | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901725) |
| October 26, 2026 | NCT07896265 | Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Overweight or Obesity Without Diabetes | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265) |
| October 21, 2026 | NCT07887750 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887750) |
| October 15, 2026 | NCT07876505 | Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations | Regeneron Pharmaceuticals | Phase 1 | Not yet recruiting | Healthy Volunteers | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876505) |
| October 15, 2026 | NCT07876492 | A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Secondary Stroke | 6,106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876492) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| October 6, 2026 | NCT07861152 | Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) | Regeneron Pharmaceuticals | Phase 1 | Not yet recruiting | Graves' Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861152) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| September 30, 2026 | NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Cancer, mCRPC | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850921) |
| September 22, 2026 | NCT07832370 | A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Prion Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832370) |
| September 21, 2026 | NCT07830329 | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or... | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Hidradenitis Suppurativa | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830329) |
| September 9, 2026 | NCT07808515 | A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Locally Advanced Basal Cell Carcinoma | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808515) |
| August 21, 2026 | NCT07780110 | Compassionate Use of Vonsetamig | Regeneron Pharmaceuticals | Not applicable | Available | Plasma Cell Mediated, Antibody Mediated | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780110) |
| August 12, 2026 | NCT07759167 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | Regeneron Pharmaceuticals | Phase 1 | Recruiting | End-Stage Kidney Disease (ESKD) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759167) |
| August 7, 2026 | NCT07753148 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic... | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753148) |
| July 17, 2026 | NCT07710846 | A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy | Regeneron Pharmaceuticals | Observational | Not yet recruiting | Conjunctivitis Allergic | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710846) |
| July 13, 2026 | NCT07697599 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted... | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 1,908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697599) |
| July 6, 2026 | NCT07685808 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Overweight or Obesity | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685808) |
| June 30, 2026 | NCT07675824 | REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | 271 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675824) |
| June 30, 2026 | NCT07675811 | A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic... | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Allergic Conjunctivitis | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675811) |
| June 8, 2026 | NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, MASH | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631637) |
| June 4, 2026 | NCT07626411 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Atrial Fibrillation (AF) | 15,364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626411) |
| May 27, 2026 | NCT07609940 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | Regeneron Pharmaceuticals | Phase 4 | Recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609940) |
| May 18, 2026 | NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594106) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 117 |
| Phase 1/2 | 34 |
| Phase 2 | 96 |
| Phase 2/3 | 11 |
| Phase 3 | 94 |
| Phase 4 | 12 |
| Not applicable | 21 |
| Observational | 27 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 213 |
| Recruiting | 70 |
| Terminated | 45 |
| Active not recruiting | 40 |
| Withdrawn | 13 |
| Not yet recruiting | 13 |
| Approved for marketing | 7 |
| Available | 7 |
| No longer available | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 29 |
| Recurrence | 18 |
| Carcinoma, Non-Small-Cell Lung | 16 |
| Lymphoma, Follicular | 15 |
| Multiple Myeloma | 14 |
| COVID-19 | 13 |
| Lymphoma, Large B-Cell, Diffuse | 12 |
| Hypercholesterolemia | 12 |
| Melanoma | 12 |
| Eczema | 11 |
| Neoplasm Metastasis | 11 |
| Macular Degeneration | 10 |
| Hemoglobinuria, Paroxysmal | 10 |
| Osteoarthritis, Knee | 9 |
| Non-alcoholic Fatty Liver Disease | 9 |
| Obesity | 9 |
| Venous Thromboembolism | 8 |
| Neoplasms | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Gout | 7 |
| Eosinophilic Esophagitis | 7 |
| Coronavirus Infections | 7 |
| Genetic Diseases, Inborn | 7 |
| Asthma | 7 |
| Fallopian Tube Neoplasms | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
